The 2nd Precision Medicine Congress

ENABLING SUCCESSFUL IMPLEMENTATION THROUGH BIOMARKER, CDx, GENOMIC AND BIG DATA RESEARCH

Following on from the success of the inaugural meeting which attracted over 150 key senior attendees, Global Engage is pleased to announce the 2nd Precision Medicine Congress which will be held on September 14-15, 2015 in London, UK at the London Heathrow Hotel. The meeting is part of our successful Drug Discovery series which includes innovative meetings on Digital Health, Digital Pathology, Human Microbiome, Synthetic Biology, qPCR/dPCR, & Biologics among others. www.globalengage.co.uk/events/

Recent advancements in the biomarker, CDx genomic and big data space have meant that some of the fundamental challenges of precision medicine are being realised. The potential for personalized medicine and therefore the possibility of delivering superior outcomes for patients is in reach. There is, however, a lot more to do. Alongside the continued developments in science as well as improvements in clinical trial design, support mechanisms such as market access /reimbursement/ regulatory strategies need to be further developed. Continued work by all stakeholders is therefore vital for success.

The congress has been purposely designed for a variety of audiences from drug and DX developers, payers, healthcare providers, academics to technology solution providers.

Attracting experts working in all areas of precision and personalised medicine such as biomarkers, CDx, translational medicine, clinical trials, genomics, NGS, bioinformatics and health economics, this two day interactive meeting will provide you the opportunity to take home cutting edge knowledge and insights from the presenters as well as to network and exchange views with your peers.

Recent advancements in the biomarker, CDx genomic and big data space have meant that some of the fundamental challenges of precision medicine are being realised. The potential for personalized medicine and therefore the possibility of delivering superior outcomes for patients is in reach. There is, however, a lot more to do. Alongside the continued developments in science as well as improvements in clinical trial design, support mechanisms such as market access /reimbursement/ regulatory strategies need to be further developed. Continued work by all stakeholders is therefore vital for success.

The congress has been purposely designed for a variety of audiences from drug and DX developers, payers, healthcare providers, academics to technology solution providers.

Attracting experts working in all areas of precision and personalised medicine such as biomarkers, CDx, translational medicine, clinical trials, genomics, NGS, bioinformatics and health economics, this two day interactive meeting will provide you the opportunity to take home cutting edge knowledge and insights from the presenters as well as to network and exchange views with your peers.

Confirmed Speakers Include:

- Leroy Hood
  President, Institute of Systems Biology
- Richard Barker
  Chairman of the Precision Medicine Catapult, founding Director of CASMI
- Martina Kaufman
  Managing Director, Martina Kaufmann Consulting
- Menelas N Pangalos
  EVP, Innovative Medicines & Early Development, AstraZeneca

Conference Synopsis

Day 1 Stream 1
Strategies & Technologies to Enable Successful Implementation of Precision Medicine
- Precision Medicine approaches – Taking the next steps
- Deliver superior outcomes for patients through precision Medicine
- Economics for precision medicine - Adding value
  o Incentivising pricing &reimbursement strategies
  o Market access considerations
- IP concerns / Regulations - US & European differences
- Adaptive Licensing
- Ethical &regulatory implications of individualizing medicine
- Biomarker discovery, development & validation strategies
- Innovative clinical trials
- Technologies to enable Precision Medicine
- Panel Discussion –Future of Precision Medicine

Day 1 Stream 2
- Precision Medicine Therapeutic Case Studies
- Biomarker Case Studies
- Oncology, CNS, Immunology, Respiratory etc
- Create targeted treatments based patients’ genetic profiles
- Multiplexed assays for cancer development
- Tumour heterogeneity
- Oncology / CNS CDx strategies
- CNS Diagnostic Imaging

Day 2 Stream 1
Biomarker & Companion Diagnostics Development to Deliver Precision Medicine
- Delivering a successful biomarker strategy alongside developing a companion diagnostic
- CDx strategies and accelerating development
- Choosing a CDx platform
- Commercialization of CDx
- Diagnostic regulation in personalised medicine
- Biomarker Identification technologies
- Molecular profiling technologies
- Panel Discussion – Choosing & Managing Rx-Dx Partnerships

Day 2 Stream 2
Integrating Personal Genomics, Big Data and Bioinformatics
- Integrating data into personalised medicine decision making
- Linking NGS / microarray / other technologies to the bedside
- Preventive precision medicine
- Analyzing genetic mutation
- Effective data interpretation and clinical decision support
- Clinical biomarker data analysis
- Successful collection storage and analysis of data
- Big data analytics – Big data into useful data
- Biobanking
- Panel Discussion: Big Data, Technologies &Methods to Improve Data Integration for Precision Medicine
## Confirmed Speakers

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Company/Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leroy Hood, President, Institute of Systems Biology</td>
<td>served as the President of the Institute of Systems Biology and is a renowned figure in the field of systems biology.</td>
</tr>
<tr>
<td>Marvin Caruthers, Distinguished Professor of Chemistry and Biochemistry, University of Colorado</td>
<td>with a career spanning over four decades, he has made significant contributions to the fields of chemistry and biochemistry.</td>
</tr>
<tr>
<td>Menelas N Pangalos, EVP, Innovative Medicines &amp; Early Development, AstraZeneca</td>
<td>an experienced executive in the biopharmaceutical industry, leading the company's early development efforts.</td>
</tr>
<tr>
<td>Richard Barker, Chairman of the Precision Medicine Catapult</td>
<td>an accomplished executive and leader in the precision medicine field.</td>
</tr>
<tr>
<td>Ketan Patel, Product Strategist Precision Medicine, Oracle Health Sciences</td>
<td>as a strategic leader in the healthcare industry, he focuses on developing innovative solutions for precision medicine.</td>
</tr>
<tr>
<td>Michel Goldman, former IMI Executive Director and now Professor of Pharmacotherapy at the Université Libre de Bruxelles, Belgium</td>
<td>a distinguished academic and a former Executive Director of the Innovative Medicines Initiative (IMI).</td>
</tr>
<tr>
<td>Baitang Ning, Division of Systems Biology, NCTR/FDA</td>
<td>as a principal scientist, he leads the Division of Systems Biology at NCTR/FDA.</td>
</tr>
<tr>
<td>David M Jackson, VP - Diagnostics / Companion Diagnostics, Arno Therapeutics, Inc</td>
<td>as a key executive in the biopharmaceutical sector, he is instrumental in developing diagnostic tools.</td>
</tr>
<tr>
<td>Robin Sherrington, SVP, Business &amp; Corporate Development, Xenon Pharmaceuticals Inc</td>
<td>an experienced executive in the biotech industry.</td>
</tr>
<tr>
<td>Senior Representative, NanoString Technologies</td>
<td>serves as a representative for NanoString Technologies.</td>
</tr>
<tr>
<td>Senior Representative, Intomics</td>
<td>serves as a representative for Intomics.</td>
</tr>
<tr>
<td>Jonathan Lewis, Chief Executive Officer &amp; Director, ZiOPHARM Oncology</td>
<td>as a leader in the oncology sector, he plays a crucial role in advancing precision medicine in oncology.</td>
</tr>
<tr>
<td>Niven Narain, Co-Founder, President &amp; CTO, Berg Pharma</td>
<td>a co-founder and president of Berg Pharma, he has been instrumental in building the company.</td>
</tr>
<tr>
<td>Omar Laterza, Director of Immunoassay and Mass Spectrometry, Molecular Biomarkers and Diagnostics Laboratory, Merck</td>
<td>as a leader in the field of molecular diagnostics, he has made significant contributions to the development of diagnostic assays.</td>
</tr>
<tr>
<td>Elaine Kilgour, Associate Director, Oncology Translational Science, AstraZeneca</td>
<td>as an associate director, she leads the oncology translational science team.</td>
</tr>
<tr>
<td>Krishna Kalari, Assistant Professor of Medical Informatics, Department of Health Sciences Research, Mayo Clinic</td>
<td>as an assistant professor, he contributes to the advancement of medical informatics.</td>
</tr>
<tr>
<td>Hans Lerach, Professor, Max Planck Institute for Molecular Genetics, Germany</td>
<td>as a leading figure in the field of molecular genetics, he has made significant contributions to the understanding of various genetic conditions.</td>
</tr>
<tr>
<td>George Vasmatzis, co-director, Biomarker Discovery Program, Center for Individualized Medicine, Mayo Clinic</td>
<td>as a co-director, he leads the Biomarker Discovery Program at Mayo Clinic.</td>
</tr>
<tr>
<td>Jennifer Dudinak, Vice President, Global Regulatory Affairs, Head, Pharma Regulatory Therapeutic Team, GlaxoSmithKline, Research and Development</td>
<td>as a vice president, she oversees the global regulatory affairs team.</td>
</tr>
<tr>
<td>Xuemei Zhao, Principal Scientist, Translational Biomarkers Merck</td>
<td>as a principal scientist, she contributes to the development of translational biomarkers.</td>
</tr>
<tr>
<td>Senior Representative, Silicon Biosystems</td>
<td>serves as a representative for Silicon Biosystems.</td>
</tr>
<tr>
<td>Senior Representative, Quintiles</td>
<td>serves as a representative for Quintiles.</td>
</tr>
<tr>
<td>Senior Representative, Covance</td>
<td>serves as a representative for Covance.</td>
</tr>
<tr>
<td>Senior Representative, FerrinCode</td>
<td>serves as a representative for FerrinCode.</td>
</tr>
</tbody>
</table>

For more information please contact Nick Noakes, Marketing Director, Global Engage Ltd.

nnoakes@globalengage.co.uk  +44 (0) 1865 849841
Sponsors, Supporters and Media Partners

Platinum Sponsors

![Intomics](image1)
![NanoString](image2)

Silver Sponsors

![Covance](image3)
![Ferrer inCode](image4)
![Silicon Biosystems](image5)

Sponsors

![GenomicsNet](image6)
![Oracle Health Sciences](image7)
![Quintiles](image8)

Media Partners

![Bentham Science](image9)
![GBi](image10)

Venue

London Heathrow Marriott Hotel
Bath Road
Hayes
UB3 5AN
United Kingdom

A special rate will be available on registration.

For more information please visit our website for details - [www.globalengage.co.uk/precision/venue.html](http://www.globalengage.co.uk/precision/venue.html)

For more information please contact Nick Noakes, Marketing Director, Global Engage Ltd.
nnoakes@globalengage.co.uk +44 (0) 1865 849841
08.00-08.50 Registration & Coffee

08.50-09.00 Welcome Address
Track Chair - Thomas Wilckens, CSO & Founder, InnVentis

09.00-09.40 Keynote Address
**Proactive P4 Medicine: Catalyzing a Revolution in Healthcare through a Longitudinal, High-dimensional Data Study of 100,000 Person Wellness Project**

Systems medicine has reached a tipping point and is already beginning to transform the practice of medicine. Three converging opportunities—systems medicine, big data (and its analytics) and patient-activated social networks—are leading to a proactive medicine that is predictive, personalized, preventive and participatory (P4). P4 medicine has two central thrusts—quantifying wellness and demystifying disease. I will contrast P4 medicine with contemporary evidence-based medicine and discuss its societal implications for healthcare. I will discuss how we plan to introduce P4 medicine into the current healthcare system with a P4 pilot program—a longitudinal, high-dimensional data cloud study on 100,000 well patients. We have already generated and analyzed the dynamical data clouds for a year on 105 well individuals. The preliminary results from these studies are striking. This approach can be used to study any disease—and I will give several illustrations including Alzheimer’s Disease. These advances will have profound implications for healthcare and society.

Confirmed:
Leroy Hood, President, Institute of Systems Biology, USA

09.40-10.20 Keynote Address
**Harnessing the Power of Genomics to Deliver the Promise of Personalised Healthcare**

Personalised healthcare (PHC) is an integral part of our R&D activities at AstraZeneca. Today more than 80% of our clinical pipeline has a PHC component and our teams have already demonstrated what genomic science can do across our oncology portfolio. However, we know that this is only the start. This is why we are working collaboratively with our industry and academic partners to harness the latest breakthroughs in genomics that will enable us to deliver the next generation of precision medicines and companion diagnostics with the potential to transform the lives of patients around the world.

Confirmed:
Menelas N Pangalos, EVP, Innovative Medicines & Early Development, AstraZeneca

10.20-10.50 Solution Provider Presentation
Title to be Confirmed

10.50-12.00 Morning Refreshments
Poster Presentation Sessions
One to One Meetings

**Strategies & Technologies to Enable Successful Implementation Of Precision Medicine**

Track Chair - Thomas Wilckens, CSO & Founder, InnVentis

Fitting The Treatment to Patients: Personalized Healthcare Strategies at Roche in Oncology – Title to be Confirmed
Confirmed
Felix Fruhe, Chief Scientific Officer, Human Longevity, Inc

The story of clinical development of Arno’s lead oncology drug and companion diagnostic
Confirmed
Miro Venturi, Global Head Diagnostic Biomarkers, Roche

Implementation of FISH based selection of FGFR inhibitor AZD4547.

Examples of recent patient selection approaches in AstraZeneca oncology

Focus on lessons learned from FGFR project experience including:

Hypothesis development in preclinical models

Clinical implementation including highlighting the challenges of implementing prospective screening for low prevalence patient populations in clinical studies

Analysis of the actual trial population wrt FGFR gene amplification, expression and comparison to preclinical models

Discussion of the challenge that tumour heterogeneity present for the selection of amplified pts by FISH and one approach to assessing intra-tumoural heterogeneity by automated image analysis of FISH

Confirmed:
Andreas Wallnöfer, Senior Vice President, pRED – Roche Pharma Research & Early Development, F. Hoffmann-La Roche

For sponsorship opportunities please contact Steve Hambrook at steve@globalengage.co.uk

**Strategies & Technologies to Enable Successful Implementation Of Precision Medicine**

Track Chair - Martina Kaufmann, Managing Director, Martina Kaufmann Strategic Consulting

For sponsorship opportunities please contact Steve Hambrook at steve@globalengage.co.uk

13.30-14.30 Lunch
One to One Meetings

14.30-15.00 Title to be Confirmed

For more information please contact Nick Noakes, Marketing Director, Global Engage Ltd.

nnoakes@globalengage.co.uk +44 (0) 1865 849841
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.00-15.30</td>
<td>Interdisciplinary Innovation: Moving The Yardsticks of Medical Research</td>
<td>The implementation of precision medicine in the standard of care requires disruptive changes among all stakeholders. In this presentation, we will focus on the need of unprecedented collaborative initiatives to foster interdisciplinary innovation beyond the classical boundaries of biomedical research. Confirmed: Michel Goldman, former IMI Executive Director and now Professor of Pharmacotherapy at the Université Libre de Bruxelles, Belgium. Confirmed: Thomas Metcalfe, Project Leader, Roche Pharma Regulatory.</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Solution Provider Presentation Title to be Confirmed</td>
<td>Solution Provider Presentation Title to be Confirmed</td>
</tr>
<tr>
<td>16.00-16.50</td>
<td>Afternoon Refreshments Poster Presentation Sessions One to One Meetings</td>
<td>For sponsorship opportunities please contact Steve Hambrook at <a href="mailto:steve@globalengage.co.uk">steve@globalengage.co.uk</a></td>
</tr>
<tr>
<td>16.50-17.20</td>
<td>Solution Provider Presentation Title to be Confirmed</td>
<td>Solution Provider Presentation Title to be Confirmed</td>
</tr>
<tr>
<td>17.20-17.50</td>
<td>Panel Discussion – Future of Precision Medicine</td>
<td>Circulating clinical biomarkers: from protein to microRNA</td>
</tr>
<tr>
<td></td>
<td>Confirmed: Martina Kaufmann, Managing Director, Martina Kaufmann Strategic Consulting</td>
<td>• Circulating protein marker discovery</td>
</tr>
<tr>
<td></td>
<td>Confirmed: Thomas Wilckens, CSO &amp; Founder, InnVentis</td>
<td>• Circulating microRNA marker discovery</td>
</tr>
<tr>
<td></td>
<td>Confirmed: Jonathan Lewis, Chief Executive Officer &amp; Director, ZIOPHARM Oncology</td>
<td>• Influence of blood matrices on circulating biomarker discovery</td>
</tr>
<tr>
<td></td>
<td>Invitation to: Senior Representatives x3</td>
<td>Confirmed: Xuemei Zhao, Principal Scientist, Translational Biomarkers Merck</td>
</tr>
<tr>
<td>17.50-18.20</td>
<td>Pharmacogenetics and Precision Medicine: Using NGS Technology to Interrogate Genetic Variants Responsible for Drug Efficacy and Drug Safety</td>
<td>Title to be Confirmed</td>
</tr>
<tr>
<td></td>
<td>Confirmed: Baitang Ning, Division of Systems Biology, NCTR/FDA</td>
<td>Confirmed: Robin Sherrington, SVP, Business &amp; Corporate Development, Xenon Pharmaceuticals Inc</td>
</tr>
<tr>
<td>18.20-18.50</td>
<td>Title to be Confirmed</td>
<td>Variable short tandem repeat [STR] polymorphisms to identify associations related to several neurodegenerative diseases</td>
</tr>
<tr>
<td></td>
<td>Confirmed: Andres Metspalu, Professor and Director Estonian Genome Center, University of Tartu, Estonia</td>
<td>Reserved: Allen D. Roses, Jefferson-Pilot Distinguished Professor of Neurobiology and Neurology, Duke University &amp; President and CEO, Zinfandel Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>18.50-19.50</td>
<td>Networking Drinks Reception</td>
<td>Chairman’s Closing Remarks and End of Day 1</td>
</tr>
</tbody>
</table>
**Track Chair** - David M Jackson, VP - Diagnostics / Companion Diagnostics, Arno Therapeutics, Inc

08.40-09.20 **Keynote Address**
Title to be Confirmed

Confirmed:
Richard Barker, Chairman of the Precision Medicine Catapult, founding Director of the Centre for the Advancement of Sustainable Medical Innovation (CASMI) and former Director General of the Association of the British Pharmaceutical Industry

09.20-10.00 **Keynote Address**
**Synthesis and Applications of Long DNAs/RNAs/Certain Analogs**

In a collaboration with Agilent Technologies, we have developed methods and instruments for the synthesis of DNA and RNA containing up to 300 nucleotides per segment. Applications include biological research on genomes, RNA for CRISPR/Cas9 applications, and data storage. Research in the Caruthers’ laboratory has led to the use of boranephosphonate DNA as a useful synthon for generating analogs such as imidoamidates, amidates, triesters, phosphonates, thiophosphates, boranephosphamidates, and morpholino DNAs. Borane phosphonates have also been used to deposit, via a redox reaction, gold or silver on to DNA arrays and nanotubes as well as to identify intracellular sequences on genomes and RNA.

Confirmed:
Marvin Caruthers, Distinguished Professor of Chemistry and Biochemistry, University of Colorado

---

### Bimarkers & Companion Diagnostics Development to Deliver Precision Medicine

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>David M Jackson, VP - Diagnostics / Companion Diagnostics, Arno Therapeutics, Inc</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Title to be Confirmed</th>
</tr>
</thead>
</table>

**Track Chair** - David M Jackson, VP - Diagnostics / Companion Diagnostics, Arno Therapeutics, Inc

09.00-10.00 **Solution Provider Presentation**
**Storing and Analysing thousands of human genomes: Challenges and Opportunities**

All around the world there is an explosion of large genomics projects collecting the genomic data of several thousands of individuals. The genomic data when integrated with clinical phenotypic data from electronic medical records and deep phenotyping will yield a large dataset of genotype-phenotype data. In this talk we highlight some of the challenges of scale in developing datasets of this size and how the integration and query of these vast datasets will yield new insights into the molecular basis of disease. We will provide some examples of large scale projects which are happening today, and how the data is being stored, integrated and analysed.

Confirmed:
Ketan Patel, Product Strategist Precision Medicine, Oracle Health Sciences

---

**Biomarkers & Companion Diagnostics Development to Deliver Precision Medicine**

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Liz Milward, A_/Professor, Deputy President Academic Senate (Research), School of Biomedical Sciences and Pharmacy, University of Newcastle, Australia</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Title to be Confirmed</th>
</tr>
</thead>
</table>

**Track Chair** - Liz Milward, A_/Professor, Deputy President Academic Senate (Research), School of Biomedical Sciences and Pharmacy, University of Newcastle, Australia

10.00-10.30 **Solution Provider Presentation**
**Storing and Analysing thousands of human genomes: Challenges and Opportunities**

All around the world there is an explosion of large genomics projects collecting the genomic data of several thousands of individuals. The genomic data when integrated with clinical phenotypic data from electronic medical records and deep phenotyping will yield a large dataset of genotype-phenotype data. In this talk we highlight some of the challenges of scale in developing datasets of this size and how the integration and query of these vast datasets will yield new insights into the molecular basis of disease. We will provide some examples of large scale projects which are happening today, and how the data is being stored, integrated and analysed.

Confirmed:
Ketan Patel, Product Strategist Precision Medicine, Oracle Health Sciences

---

10.30-11.40 **Morning Refreshments**
**Poster Presentation Sessions**
**One to One Meetings**

---

**Biomarkers & Companion Diagnostics Development to Deliver Precision Medicine**

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Federico Goodsaid, Vice President, Strategic Regulatory Intelligence, Vertex Pharmaceuticals</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Title to be Confirmed</th>
</tr>
</thead>
</table>

Reservad:
Federico Goodsaid, Vice President, Strategic Regulatory Intelligence, Vertex Pharmaceuticals

11.40-12.10 **Solution Provider Presentation**
**Storing and Analysing thousands of human genomes: Challenges and Opportunities**

All around the world there is an explosion of large genomics projects collecting the genomic data of several thousands of individuals. The genomic data when integrated with clinical phenotypic data from electronic medical records and deep phenotyping will yield a large dataset of genotype-phenotype data. In this talk we highlight some of the challenges of scale in developing datasets of this size and how the integration and query of these vast datasets will yield new insights into the molecular basis of disease. We will provide some examples of large scale projects which are happening today, and how the data is being stored, integrated and analysed.

Confirmed:
Ketan Patel, Product Strategist Precision Medicine, Oracle Health Sciences

---

**Regulatory**

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Jennifer Dudinak, Vice President, Global Regulatory Affairs, Head, Pharma Regulatory Therapeutic Team, GlaxoSmithKline, Research and Development</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Title to be Confirmed</th>
</tr>
</thead>
</table>

From Big DATA to Precision Medicine: Tackling chronic diseases
- How to tackle polygenic chronic disease beyond genomics; longitudinal versus cohort based translational studies
- The data deluge: How AI supports R&D and patient stratification: Pattern Diagnostics
- SOPs, a key value driver for multi-omics guided R&D

Confirmed:
Jennifer Dudinak, Vice President, Global Regulatory Affairs, Head, Pharma Regulatory Therapeutic Team, GlaxoSmithKline, Research and Development

---

12.10-12.40 **Solution Provider Presentation**
**Storing and Analysing thousands of human genomes: Challenges and Opportunities**

All around the world there is an explosion of large genomics projects collecting the genomic data of several thousands of individuals. The genomic data when integrated with clinical phenotypic data from electronic medical records and deep phenotyping will yield a large dataset of genotype-phenotype data. In this talk we highlight some of the challenges of scale in developing datasets of this size and how the integration and query of these vast datasets will yield new insights into the molecular basis of disease. We will provide some examples of large scale projects which are happening today, and how the data is being stored, integrated and analysed.

Confirmed:
Ketan Patel, Product Strategist Precision Medicine, Oracle Health Sciences

---

12.40-13.10 **Solution Provider Presentation**
**Storing and Analysing thousands of human genomes: Challenges and Opportunities**

All around the world there is an explosion of large genomics projects collecting the genomic data of several thousands of individuals. The genomic data when integrated with clinical phenotypic data from electronic medical records and deep phenotyping will yield a large dataset of genotype-phenotype data. In this talk we highlight some of the challenges of scale in developing datasets of this size and how the integration and query of these vast datasets will yield new insights into the molecular basis of disease. We will provide some examples of large scale projects which are happening today, and how the data is being stored, integrated and analysed.

Confirmed:
Ketan Patel, Product Strategist Precision Medicine, Oracle Health Sciences

---

13.10-14.05 **Lunch**
**One to One Meetings**
14.05-14.20  Solution Provider Presentation
Title to be Confirmed

Confirmed:
Tony Bartlett, Director, European Commercial Operations & Collaborations, SomaLogic, Inc.

SomaLogic

Solution Provider Presentation
Digital Precision in Analysis of Tumor FFPE Specimens: The Time is Now
- Understanding current limitations associated with FFPE analysis
- Technical overview of the DEPArray (TM) platform
- Application of DEPArray (TM) sorted FFPE specimens to clinical assays

Confirmed:
Farideh Bischoff, Executive Director of Scientific Affairs, SiliconBiosystems

14.20-14.50  Title to be confirmed

Confirmed:
George Vassmatzis, co-director, Biomarker Discovery Program, Center for Individualized Medicine, Mayo Clinic, USA

14.50-15.20  Title to be Confirmed

Reserved:
Anne-Marie Martin, Head, Precision Medicine & Diagnostics Head, Molecular Medicine, Oncology R&D, GSK

15.20-15.45  Afternoon Refreshments
Poster Presentation Sessions

15.45-16.15  Collaborating to Deliver Personalized Medicine
- Collaboration strategies for drug and diagnostic partnerships
- Challenges with co-developing drugs and diagnostics
- AZ’s Personalized Healthcare Partnering Update

Confirmed
Nicole St Jean, Corporate Business Development, Global Product & Portfolio Strategy, AstraZeneca

The Virtual Patient, the key to a Truly Personalised Medicine AND Prevention
- Virtual patient, systems medicine, patient-omics

Confirmed
Hans Lerach, Professor, Max Planck Institute for Molecular Genetics, Germany

16.15-16.45  Title to be Confirmed

Reserved:
Andreas Köehler, Head Pharmacogenomics, Boehringer Ingelheim

Novel Computational Approach – PANOPLY: Precision Cancer Genomic Report: A Single Sample Inventory
With the advent of high throughput technologies, the quantity of ‘omics’ data has rapidly increased, creating the need for methodologies that can analyze complex datasets and provide interpretations that assist in decision making. We have developed PANOPLY, a novel computational approach to integrate both germline and somatic data obtained from multi-omics platforms and to analyze those data in the context of reference or control datasets.

Confirmed
Krishna Kalari, Assistant Professor of Medical Informatics, Department of Health Sciences Research, Mayo Clinic

16.45-17.15  Title to Be Confirmed

Reserved:
Head Precision Medicine Program, Cancer Research UK Centre for Drug Development, UK

Big Data Analytics is the Daily Reality in Clinical Trials at Berg
- Multi-omic and phenotypic data is invaluable resource for clinically actionable information in early stage human trials
- Artificial intelligence based analytics are successfully employed in predictive data analysis of patient molecular and medical data
- Can we create innovative clinical trial workflows leading to companion DX discovery and proof of concept verification in phase I-ll and validation in phase III?

Confirmed
Slava Akmaev, Chief Analytics Officer, Senior Vice President, Berg Pharma

Chairman’s Closing Remarks and Conference Close